BTAI - CIK 0001720893
The table below shows BioXcel Therapeutics, Inc.'s balance sheet by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $17.18M | $36.18M | $17.43M | $31.01M | $40.39M | $56.27M |
| Short-term investments | - | - | - | - | - | - |
| Receivables | - | - | - | - | - | - |
| Inventory | $500.00K | $459.00K | $506.00K | $642.00K | $1.52M | $2.68M |
| Total current assets |
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $33.91M |
| $44.40M |
| $25.24M |
| $37.78M |
| $47.79M |
| $64.18M |
| Property, plant & equipment | $117.00K | $249.00K | $324.00K | $399.00K | $552.00K | $629.00K |
| Goodwill | - | - | - | - | - | - |
| Total assets | $34.02M | $44.79M | $25.79M | $38.57M | $48.89M | $65.44M |
| Accounts payable | $16.25M | $16.28M | $16.69M | $15.45M | $14.89M | $13.26M |
| Total current liabilities | $54.99M | $37.80M | $33.38M | $25.55M | $25.56M | $27.29M |
| Long-term debt | $77.86M | $92.30M | $97.47M | $99.92M | $104.44M | $103.01M |
| Total liabilities | $139.57M | $133.71M | $133.46M | $128.74M | $134.53M | $139.74M |
| Retained earnings | -$732.78M | -$707.55M | -$676.64M | -$657.45M | -$639.34M | -$625.69M |
| Total equity | -$105.54M | -$88.92M | -$107.67M | -$90.17M | -$85.63M | -$74.30M |